GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 17, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on June 17, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- June 2025 (date) — Reporting period
- June 17, 2025 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically reporting on transactions in its own shares.
Who is acting as GSK's corporate stockbroker for these transactions?
Merrill Lynch International is acting as GSK's corporate stockbroker for the purchase of its own shares.
On what date was this report filed?
This report was filed on June 17, 2025.
What type of shares did GSK purchase?
GSK purchased its ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased or the total amount spent?
No, the filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not provide the specific quantity or the total dollar amount in the provided text.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 17, 2025 regarding GSK plc (GLAXF).